Details

Autor(en) / Beteiligte

• Vennemann, Matthias
• Ruland, Vincent
• Kruse, Jan-Philip
• Harloff, Christine
• Trübel, Hubert
• Gielen-Haertwig, Heike

Titel

Future unmet medical need as a guiding principle for pharmaceutical R&D

Ist Teil von

• Drug discovery today, 2019-09, Vol.24 (9), p.1924-1929

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2019

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •Novel methodology to systematically assess unmet medical need.•Unmet medical need is determined by the expected future standard of care.•Future unmet medical need impacts the value of a pharmaceutical development project.•Six dimensions as key drivers of patient unmet medical need have been defined.•Structured expert assessment techniques can guide R&D portfolio strategies. In pharmaceutical R&D the strategic focus is on addressing areas of high unmet medical need. ‘Unmet medical need’ is a widely used term in the healthcare sector but a common definition does not exist. The current standard of care determines the current unmet medical need, whereas the future unmet medical need (i.e., the unmet medical need when a new product reaches the market) and the extent to which the unmet need is addressed by the new product significantly impact its value. We have defined six dimensions as key drivers of (future) unmet medical needs of patients in a given setting. In the absence of quantifiable criteria, structured expert assessment techniques, such as the Delphi method, can guide portfolio strategies, especially for early-stage assets.